An enzyme‐linked immunosorbent assay (ELISA) was developed in‐house to examine plasma IgG antibodies for three linear peptide antigens derived from BIRC5a, BIRC5b, and MYC in 211 patients with NSCLC and 200 control subjects. Here, MYC is linked to non-small cell lung carcinoma.